The geriatric population represents a growing segment of patients with treatment-resistant depression, chronic pain, and other conditions for which low-dose ketamine therapy is increasingly considered. However, age-related physiological changes alter ketamine pharmacokinetics, amplify cardiovascular risks, and introduce unique neurocognitive vulnerabilities that necessitate modified clinical approaches. This review synthesizes available evidence and expert consensus on the safe and effective use of subanesthetic ketamine in elderly patients, defined here as adults aged 65 years and older.
Age-Related Pharmacokinetic Changes
Hepatic Metabolism
Ketamine is a high-extraction-ratio drug cleared primarily by hepatic blood flow and enzymatic biotransformation via CYP3A4 and CYP2B6. Aging is associated with progressive reductions in both hepatic blood flow (approximately 0.3 to 1.5 percent decline per year after age 25) and hepatic parenchymal mass. Phase I oxidative metabolism, upon which ketamine's N-demethylation to norketamine depends, is disproportionately affected by aging relative to Phase II conjugation reactions. The net effect is a reduction in ketamine systemic clearance estimated at 20 to 30 percent in adults over age 65 compared with younger adults, resulting in higher peak plasma concentrations and prolonged elimination half-life at equivalent weight-based doses.
The clinical implication is straightforward: standard adult dosing regimens (0.5 mg/kg IV over 40 minutes) may produce supratherapeutic drug exposure in elderly patients, increasing the duration and intensity of dissociative, cardiovascular, and sedative effects.
Volume of Distribution
Age-related changes in body composition -- specifically, increased fat-to-lean mass ratio and decreased total body water -- alter the distribution of lipophilic drugs. Ketamine's moderate lipophilicity results in expanded distribution into adipose tissue in elderly patients, which may prolong the terminal elimination half-life as drug slowly redistributes from fat stores back into plasma. Simultaneously, reduced lean body mass means that weight-based dosing using total body weight may overestimate the appropriate dose. Some practitioners advocate dosing based on ideal body weight (IBW) or adjusted body weight in elderly patients, particularly those who are obese or sarcopenic.
Protein Binding
Plasma protein binding of ketamine is relatively low (12 to 47 percent), primarily to alpha-1-acid glycoprotein (AAG) and albumin. Elderly patients frequently have reduced serum albumin due to chronic illness, malnutrition, or hepatic synthetic dysfunction, which increases the free (unbound) fraction of ketamine in plasma. Since only unbound drug is pharmacologically active, reduced protein binding effectively increases drug activity at a given total plasma concentration. This effect is quantitatively modest for ketamine compared with highly protein-bound drugs but may contribute to the overall increase in drug sensitivity observed in older patients.
Renal Elimination
While ketamine itself is primarily hepatically eliminated, its metabolites -- norketamine, hydroxynorketamine, and glucuronide conjugates -- are renally excreted. Age-related decline in glomerular filtration rate (GFR), which decreases by approximately 1 mL/min/year after age 40, may slow metabolite clearance. The clinical significance of metabolite accumulation is uncertain but potentially relevant given emerging evidence that norketamine and (2R,6R)-hydroxynorketamine possess independent pharmacological activity.
Cardiovascular Considerations
Baseline Cardiovascular Risk
The prevalence of hypertension, coronary artery disease, heart failure, and arrhythmia increases substantially with age. Approximately 75 percent of adults over age 65 carry a diagnosis of hypertension, and the prevalence of atrial fibrillation exceeds 10 percent in those over 75. Ketamine's sympathomimetic effects -- transient elevations in systolic blood pressure of 15 to 30 mmHg, increases in heart rate of 10 to 20 beats per minute, and increased myocardial oxygen demand -- carry greater absolute risk in a population with diminished cardiovascular reserve.
Hemodynamic Monitoring
Enhanced hemodynamic monitoring is recommended for all geriatric ketamine patients. Minimum monitoring should include:
- Pre-treatment: Baseline blood pressure and heart rate. If systolic BP exceeds 160 mmHg or heart rate exceeds 100 bpm, treatment should be deferred pending blood pressure optimization.
- During infusion: Blood pressure and heart rate every 5 minutes for IV infusions. Continuous pulse oximetry. Continuous electrocardiographic monitoring for patients with known arrhythmia or structural heart disease.
- Post-infusion: Serial blood pressure and heart rate measurements every 15 minutes until return to within 10 percent of baseline, typically requiring 60 to 90 minutes of observation.
Blood Pressure Management
Prophylactic antihypertensive therapy before ketamine infusion may be considered for patients with borderline pre-treatment blood pressure. Clonidine 0.1 mg oral administered 60 minutes before infusion has been used in some protocols to attenuate ketamine-induced hypertension. Alternatively, short-acting antihypertensives such as labetalol or hydralazine should be available for reactive management of intra-procedure hypertension exceeding 180/110 mmHg.
Cognitive Concerns
Baseline Cognitive Assessment
Cognitive impairment is prevalent in the geriatric population, with mild cognitive impairment (MCI) affecting approximately 15 to 20 percent of adults over age 65 and dementia affecting 10 percent. Given that ketamine produces transient cognitive effects -- particularly impairments in attention, working memory, and executive function -- establishing a baseline cognitive status is essential for distinguishing drug-related cognitive changes from pre-existing deficits and for identifying patients at heightened risk of adverse neurocognitive events.
Recommended baseline screening instruments include:
- Montreal Cognitive Assessment (MoCA): A 10-minute screening tool sensitive to mild cognitive impairment. A score below 26 suggests cognitive impairment warranting further evaluation.
- Mini-Mental State Examination (MMSE): Widely available though less sensitive to executive and visuospatial deficits than the MoCA.
- Trail Making Test Parts A and B: Assesses processing speed and cognitive flexibility; useful for tracking interval change.
Patients with established moderate-to-severe dementia (MoCA less than 17 or equivalent) are generally poor candidates for ketamine therapy due to the inability to reliably assess treatment response and the increased risk of delirium.
Delirium Risk
Elderly patients are particularly susceptible to delirium, and ketamine's dissociative and psychotomimetic properties place them at elevated risk. Risk factors for ketamine-related delirium in the elderly include pre-existing cognitive impairment, polypharmacy (especially anticholinergic medications), sensory deficits (hearing or vision impairment), dehydration, and acute medical illness. The Confusion Assessment Method (CAM) should be applied at each treatment session. If delirium develops, ketamine therapy should be suspended, reversible precipitants addressed, and the risk-benefit ratio of continued therapy reassessed.
Neurocognitive Monitoring
Serial cognitive assessments should be incorporated into the treatment protocol for elderly patients receiving repeated ketamine treatments. A practical approach includes:
- Baseline MoCA or equivalent before treatment initiation
- Repeat cognitive screening at sessions 3, 6, and every 6 sessions thereafter
- Immediate reassessment if the patient, caregiver, or clinician reports new cognitive complaints
Any sustained decline in cognitive scores (a drop of 3 or more points on MoCA not attributable to mood-related cognitive dysfunction) should prompt treatment suspension and neurological evaluation.
Dose Modifications
Recommended Starting Dose
Expert consensus and limited clinical data support a reduced starting dose in geriatric patients. The typical recommendation is 0.3 to 0.4 mg/kg IV, compared with the standard adult dose of 0.5 mg/kg. This 20 to 40 percent dose reduction accounts for the combined effects of reduced hepatic clearance, altered volume of distribution, decreased protein binding, and increased end-organ sensitivity.
Infusion Rate
Slower infusion rates are recommended to attenuate the peak plasma concentration achieved during the infusion. Extending the infusion duration from 40 to 60 minutes at the reduced dose produces a more gradual onset of effects and reduces hemodynamic perturbation. Some practitioners use even longer infusion durations (up to 90 minutes) for particularly frail or medically complex elderly patients.
Titration Strategy
A conservative titration approach is warranted:
- Session 1: 0.3 mg/kg over 60 minutes with intensive monitoring
- Session 2: If tolerated, maintain 0.3 mg/kg or increase to 0.35 mg/kg based on clinical response and tolerability
- Sessions 3 through 6: Gradual titration to a maximum of 0.4 mg/kg if clinically indicated, with continued hemodynamic and cognitive monitoring
- Dose escalation beyond 0.4 mg/kg should be undertaken only with strong clinical justification and enhanced monitoring
Alternative Routes
For elderly patients who are poor candidates for IV infusion due to vascular access difficulties or infusion-related anxiety, alternative routes may be considered. Intranasal esketamine (Spravato) has been studied in patients over age 65 in the TRANSFORM-3 trial (Ochs-Ross et al., 2020), which demonstrated safety but did not achieve statistical significance for efficacy in the elderly subgroup, possibly due to insufficient sample size. Sublingual ketamine at doses of 0.5 to 1 mg/kg offers a less invasive route with lower peak plasma concentrations due to first-pass metabolism, though bioavailability is variable and predictability of effect is reduced.
Evidence Base
Randomized Controlled Trials
The evidence base for ketamine therapy in elderly patients is notably limited. Most landmark ketamine-for-depression RCTs have either excluded patients over age 65 or enrolled insufficient numbers to permit age-specific subgroup analyses. The TRANSFORM-3 trial of intranasal esketamine in patients aged 65 and older (N = 138) did not meet its primary efficacy endpoint, raising questions about whether the elderly require different dosing strategies, longer treatment courses, or whether the antidepressant mechanism is less robust in the aging brain. However, the study demonstrated an acceptable safety profile with enhanced monitoring.
Observational Data
Retrospective and observational studies provide a more encouraging picture. George and colleagues (2017) reported that IV ketamine at 0.5 mg/kg produced clinically meaningful antidepressant responses in patients aged 60 to 75, although response rates were numerically lower than in younger cohorts. Lenze and colleagues (2020) conducted an open-label study of serial ketamine infusions in late-life treatment-resistant depression and observed response rates of approximately 40 percent with acceptable tolerability when doses were individually titrated.
Chronic Pain in the Elderly
Ketamine for geriatric chronic pain has been studied primarily in perioperative contexts, where subanesthetic IV ketamine as an adjunct to multimodal analgesia has demonstrated opioid-sparing effects in elderly surgical patients. Extrapolation to outpatient chronic pain settings requires caution but supports the rationale for geriatric-specific dosing protocols.
Screening Protocol for Geriatric Patients
A structured screening protocol for elderly ketamine candidates should include:
- Comprehensive medical history: With emphasis on cardiovascular disease, hepatic and renal function, cognitive status, fall risk, and polypharmacy
- Baseline vital signs: Blood pressure (with orthostatic assessment), heart rate, oxygen saturation
- Electrocardiogram: For all patients over 65, regardless of cardiovascular history
- Laboratory studies: Comprehensive metabolic panel (renal and hepatic function), complete blood count, thyroid function, serum albumin
- Cognitive screening: MoCA or equivalent
- Medication reconciliation: With specific attention to anticholinergic burden (using the Anticholinergic Cognitive Burden Scale), CYP3A4 inhibitors/inducers, benzodiazepines, and opioids
- Fall risk assessment: Timed Up and Go (TUG) test or equivalent
- Caregiver/companion assessment: Availability of a responsible adult for post-treatment supervision and transportation
Clinical Recommendations
- Dose reduction is standard: Start at 0.3 mg/kg IV over 60 minutes. Do not exceed 0.4 mg/kg without compelling clinical justification.
- Enhanced monitoring: Vital signs every 5 minutes during infusion; extended observation period (90 minutes minimum post-infusion).
- Cognitive surveillance: Baseline and serial cognitive assessments are essential, not optional.
- Cardiovascular gatekeeping: Defer treatment if systolic BP exceeds 160 mmHg pre-treatment. Have short-acting antihypertensives available.
- Minimize anticholinergic co-prescribing: Review and reduce anticholinergic burden before initiating ketamine.
- Involve caregivers: Ensure a responsible companion is present for all sessions and can report on interval cognitive or behavioral changes.
- Set realistic expectations: Counsel patients and caregivers that efficacy data in the elderly are limited and that treatment is being offered on the basis of extrapolation from younger adult data with appropriate dose modification.
- Fall prevention: Assist with ambulation during and after treatment. Discharge only when gait is stable and vital signs have returned to baseline.
Conclusion
Low-dose ketamine therapy in the geriatric population is feasible but requires meaningful modifications to standard adult protocols. Age-related pharmacokinetic changes mandate dose reduction and slower infusion rates. The heightened prevalence of cardiovascular disease necessitates rigorous hemodynamic monitoring and lower treatment thresholds. Cognitive vulnerability demands systematic baseline and serial neurocognitive assessment. The limited evidence base in elderly patients underscores the importance of individualized risk-benefit analysis, conservative titration, and transparent informed consent regarding the extrapolated nature of current efficacy data. Prospective, adequately powered randomized trials specifically enrolling geriatric patients are urgently needed to establish evidence-based dosing, efficacy, and safety parameters for this growing clinical population.
References
- PubMed: Safety, Tolerability, and Real-World Effectiveness of IV Ketamine in Older Adults with TRD — Case series evaluating intravenous ketamine infusions in 53 adults aged 60+ with treatment-resistant depression
- PubMed: Effectiveness, Safety and Tolerability of Ketamine for Depression in Adolescents and Older Adults — Systematic review of ketamine for depression in special age populations including elderly patients
- American Geriatrics Society — Professional society providing clinical guidance on medication safety and dosing considerations in older adults
- MedlinePlus: Ketamine Injection Drug Information — National Library of Medicine medication information including pharmacokinetic considerations and precautions
Share